The agency said the suspension – which put the EUA application on ice – was due to missing data from the vaccine’s clinical trials
Sohini Das |
Last Updated at July 6, 2021 00:17 IST
As controversy over the $324-million deal for 20 million doses of Covaxin with Brazil brews, on Monday some reports pointed out that the Brazilian regulator had not granted Bharat Biotech — the makers of Covaxin — emergency-use authorisation (EUA).
The Hyderabad-based company’s website noted that on June 4, ANVISA — the Brazilian regulator — had authorised the “exceptional import of Covaxin by the health ministry for distribution and use under controlled conditions”.
This is a departure from the June 30 press statement wherein the company had clarified it had not received any money from Brazil’s health ministry.
On Monday, NDTV reported that ANVISA “suspended the deadline for evaluating the application for emergency use of Covaxin”. The agency said the suspension — which put the EUA application on ice — was due to missing data from the vaccine’s clinical trials. NDTV claimed that ANVISA had stressed the difference between the EUA application and authorising imports under ‘controlled conditions’.
The news channel claimed that the June 4 notice was for import of 4 million doses “which could be used only under specific conditions (as determined by the Brazilian government)”. It added that ANVISA had claimed that its decision on the EUA was held up over information gaps in the analysis of Covaxin’s data.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
First Published: Tue, July 06 2021. 00:17 IST